Is Pharming Group N.V. (PHAR) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 10.4% / 30% | 15.6% / 30% | 4.7% / 30% | 1.63% / 5% | ✓ HALAL |
| DJIM | 10.4% / 33% | 15.6% / 33% | 4.7% / 33% | 1.63% / 5% | ✓ HALAL |
| MSCI | 28.1% / 33% | 42.0% / 33% | 12.5% / 33% | 1.63% / 5% | ✗ NOT HALAL |
| S&P | 10.4% / 33% | 15.6% / 33% | 4.7% / 33% | 1.63% / 5% | ✓ HALAL |
| FTSE | 28.1% / 33% | 42.0% / 33% | 12.5% / 50% | 1.63% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 87.9% | |
| Operating Margin | 5.8% | |
| Net Margin | 0.8% | |
| Return on Equity (ROE) | 1.0% | |
| Return on Assets (ROA) | 4.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $55M |
| Free Cash Flow | $54M |
| Total Debt | $116M |
| Debt-to-Equity | 41.8 |
| Current Ratio | 2.6 |
| Total Assets | $500M |
Price & Trading
| Last Close | $16.13 |
| 50-Day MA | $16.83 |
| 200-Day MA | $14.73 |
| Avg Volume | 29K |
| Beta | 0.2 |
|
52-Week Range
$7.50
| |
About Pharming Group N.V. (PHAR)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. It has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Purification Calculator
As a halal stock with 1.63% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Pharming Group N.V. (PHAR) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Pharming Group N.V. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Pharming Group N.V.'s debt ratio?
Pharming Group N.V.'s debt ratio is 10.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 28.1%.
Does Pharming Group N.V. require dividend purification?
Yes, Pharming Group N.V. has an impermissible income ratio of 1.63%, which means 1.63% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are Pharming Group N.V.'s key financial metrics?
Pharming Group N.V. has a market capitalization of $1.1B, trailing P/E ratio of 407.8, and revenue of $376M. The company maintains a gross margin of 87.9% and a net margin of 0.8%. Return on equity stands at 1.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.